Publication
Transforming Growth Factor-b1 polymorphism is not associated with chronic graft disease: evidence from a meta-analysis
| dc.contributor.author | Lima, Bruno A. | |
| dc.contributor.author | Alves, Helena | |
| dc.date.accessioned | 2016-09-28T12:00:54Z | |
| dc.date.available | 2016-09-28T12:00:54Z | |
| dc.date.issued | 2016-05 | |
| dc.description.abstract | Kidney transplantation has been recognised as the optimal treatment choice for most end stage renal disease patients and the increase of allograft survival rates is achieved through the refinement of novel immunosuppressive agents. Chronic Graft Disease (CGD) is a multifactorial process that likely includes a combination of immunological, apoptotic and inflammatory factors. The application of individualised immunosuppressive therapies will also depend on the identification of risk factors that can influence chronic disease. Despite being the subject of several independent studies, investigations of the relationship between transforming growth factor-b1 (TGF-b1) polymorphisms and kidney graft outcome continue to be plagued by contradictory conclusions. | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.18/3969 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | John Wiley and Sons | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Kidney Transplantation | pt_PT |
| dc.subject | Chronic Graft Disease | pt_PT |
| dc.title | Transforming Growth Factor-b1 polymorphism is not associated with chronic graft disease: evidence from a meta-analysis | pt_PT |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | KOS Island, Grécia | pt_PT |
| oaire.citation.title | 30th European Immunogenetics & Histocompatibility Conference, 11-14 maio 2016 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | conferenceObject | pt_PT |